053950 — Kyung Nam Pharm Co Balance Sheet
0.000.00%
- KR₩51bn
- KR₩38bn
- KR₩61bn
Annual balance sheet for Kyung Nam Pharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 27,495 | 23,248 | 45,478 | 35,013 | 50,814 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 19,692 | 16,451 | 13,945 | 19,443 | 14,360 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 57,639 | 54,920 | 77,329 | 71,198 | 77,825 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 32,227 | 33,852 | 31,235 | 46,710 | 32,327 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 126,655 | 125,307 | 138,269 | 166,609 | 166,584 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 38,605 | 25,411 | 43,887 | 66,933 | 46,279 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 69,291 | 52,778 | 44,498 | 87,248 | 51,361 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 57,364 | 72,529 | 93,771 | 79,362 | 115,223 |
Total Liabilities & Shareholders' Equity | 126,655 | 125,307 | 138,269 | 166,609 | 166,584 |
Total Common Shares Outstanding |